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overlying hairsA 56-year-old man presented with an asymptomatic subcutane-
ous mass on the extensor side of left forearm for 2 years. On exam-
ination, a 6 cm  10 cm, ﬂesh-colored, rubberyeelastic,
multinodular subcutaneous mass was found on the left forearm.
Additionally, there were many mature hairs arising from the mass
(Figure 1). The other skin area beyond the tumor was almost bared
without overlying hairs. An incisional biopsy was performed. Path-
ologically, there were patches of myxoid change from the upper
dermis to the subcutis with pleomorphic spindle cells in the myx-
oid areas (Figure 2A and B). Some lipoblast-like and ReedeStern-
berg-like cells were also noted (Figure 2C and D). There was
mixed inﬂammatory inﬁltrate around the perivascular area with
lymphocytes, histiocytes, plasma cells, neutrophils, and multinu-
clear giant cells (Figure 2E and F). Mature hair follicles were also
noted. Mitotic ﬁgures were rarely seen. Immunohistochemical
studies showed that tumor cells were strongly positive for vimentin
and CD34, and negative for smooth muscle actin, desmin, S-100
protein, and cytokeratin. CD68 was focally positive. Based on these
histopathologic ﬁndings, myxoinﬂammatory ﬁbroblastic sarcoma
(MIFS) was diagnosed. The tumor was widely excised with a free
but close margin (about 1 mm) to the basal base and the wound
was repaired with anterolateral thigh ﬂap.
MIFS was ﬁrst reported by Montgomery 1 in 1988. Since it has
also been reported in other locations, the previous name “acral
MIFS” is no longer used in the 2002 World Health Organization
classiﬁcation. MIFS is a rare, slow-growing, ill-deﬁned subcutane-
ous painless tumormostly on the hands and feet. The tumor is often
seen inmiddle-aged adults with equal sex distribution. Generally, it
is still regarded as a low-grade tumor with a good prognosis.2e4
However, metastasis leading to death has also been reported.5
Clinically, MIFS should be differentiated from other common
subcutaneous neoplasms such as ganglion cysts, nodular fasciitis,
synovial pseudocyst, neuroﬁbroma, liposarcoma, and myxoﬁbro-
sarcoma.2,6 Histologically, it shows multinodular and poorly cir-
cumscribed tumor with prominent myxoid change and focal area
of hyalinization. It is mostly conﬁned to the dermis and subcutane-
ous tissue, although invasion of underlying fascia, tendons, and
skeletal muscle have been observed. Mixed inﬂammatory inﬁl-
trates including neutrophils, eosinophils, lymphocytes, plasma
cells, and large atypical, pleomorphic cells with vesicular nuclei;
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hemorrhage are sometimes seen.
The immunohistochemical analysis revealed vimentin, CD34,
EGFR, and CD163 diffusely positive in most cases. S-100, desmin,
actin, HMB-45, CD15, CD30, CD45, and neuron-speciﬁc endolase
are typically lacking. Vimentin is positive for mesenchymal cells
to rule out epithelium origin tumor. CD30 is used to deﬁne the
origin of Reed-Sternberg-like cells. These immunohistochemistry
stains help to distinguish this tumor from others of different ori-
gins, such as neuroendocrine tumor (ganglion cysts, neuroﬁbroma,
etc.), melanocytic tumor, and other mesenchymal tumors. CD68,
epithelial membrane antigen, and cytokeratin expression are vari-
able. No immunohistochemistry studies so far provide sufﬁcient ev-
idence in differentiating MIFS from other myxoid tumors.
The histological differential diagnosis includes: nontumor le-
sions, such as infectious and inﬂammatory process; myxoid neo-
plasms, such as nodular and proliferative fasciitis; tenosynovitis;
ganglion cyst; myxoma; inﬂammatory ﬁbrosarcoma; inﬂammatory
myoﬁbroblastic tumor ormyxoﬁbrosarcoma; hemosiderotic ﬁbroli-
pomatous tumor; and lymphoma, such as Hodgkin's lym-
phoma.2,4,5 MIFS and hemosiderotic ﬁbrolipomatous tumor share
the same molecular abnormality, including a t(1; 10) (p22; q24)
and ampliﬁcation of chromosome 3 material.7
Complete surgical resection is the ﬁrst choice of treatment, since
marginal excision and amputation had been performed forFigure 1 A ﬂesh-colored, rubberyeelastic, multinodular mass with mature overlying
hairs on the left forearm. The inserted ﬁgure shows that the hairs obviously increased
beyond the tumor.
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Figure 2 (A) Inﬂammatory inﬁltrates over the perivascular area (hematoxylin and eosin stain,100). (B) Prominent myxoid matrix overlie the tumor of hyaline stroma of biphasic
appearance and noticeable inﬂammatory cells (hematoxylin and eosin stain,20). (C) ReedeSternberg-like cell (white arrow), multinucleated giant cells, and (D) lipoblast-like cells
were noted (hematoxylin and eosin stain, 400). (E) Mixed inﬁltration with bizarre cells and red blood cells extravasation (hematoxylin and eosin stain, 400). (F) Pleomorphic
spindle cells with hyperchromatic nuclei were arranged singly and in small clusters in the myxoid areas (hematoxylin and eosin stain, 400).
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cutis, and it is hard to recognize the tumor-free surgical margin.
Narrow-margin excision, wide excision and below the elbow
amputation had all been performed. Local recurrence is common
between 3 months and 5 years after operation, ranging from 22%
to 67%. Incomplete treatment and longer follow-up time lead to
higher recurrence. Distal metastasis, death of tumor metastasis to
visceral organs, and disease progression are rarely seen but all
have been reported.5 The overall prognosis is excellent.
Interestingly, there was increased mature hair growth arising
from the tumor in this patient compared to the nontumor areas.
Mature hairs are rarely found on the dermatoﬁbroma and some
follicular tumors such as trichofolliculoma or folliculosebaceous
cystic hamartoma. MIFS with growth of mature hairs has never
been reported in the literature. We rewrite as “It might be an asso-
ciation resulted from epidermal induction”. However, the increased
overlying hairs could be a coincidence rather than an association.
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